The future belongs to those who believe in multiplex CAR T engineering

IF 19.8 1区医学 Q1 CELL & TISSUE ENGINEERING

Cell stem cell Pub Date : 2025-07-03 DOI:10.1016/j.stem.2025.06.008

Laura Volta, Chiara F. Magnani

引用次数: 0

Abstract

Toxicity and immune evasion have hindered the success of CAR T cells in HER2-positive solid tumors. In this issue of Cell Stem Cell, Hosking et al. present an iPSC-derived CAR T cell product engineered for tumor-selective targeting, resistance to the immunosuppressive tumor microenvironment, enhanced persistence and trafficking, and mitigation of antigen escape.

查看原文本刊更多论文

未来属于那些相信多重CAR - T工程的人

毒性和免疫逃避阻碍了CAR - T细胞在her2阳性实体瘤中的成功。在这一期的《细胞干细胞》中，Hosking等人提出了一种ipsc衍生的CAR - T细胞产品，该产品具有肿瘤选择性靶向，抵抗免疫抑制肿瘤微环境，增强持久性和运输，以及减轻抗原逃逸的能力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cell stem cell 生物-细胞生物学

CiteScore

37.10

自引率

2.50%

发文量

151

审稿时长

42 days

期刊介绍： Cell Stem Cell is a comprehensive journal covering the entire spectrum of stem cell biology. It encompasses various topics, including embryonic stem cells, pluripotency, germline stem cells, tissue-specific stem cells, differentiation, epigenetics, genomics, cancer stem cells, stem cell niches, disease models, nuclear transfer technology, bioengineering, drug discovery, in vivo imaging, therapeutic applications, regenerative medicine, clinical insights, research policies, ethical considerations, and technical innovations. The journal welcomes studies from any model system providing insights into stem cell biology, with a focus on human stem cells. It publishes research reports of significant importance, along with review and analysis articles covering diverse aspects of stem cell research.